Bristol-Myers Squibb clarification on didanosine supply

The Lancet

Volumn 376, Issue 9746, 2010, Pages 1054-

  Pasqualone, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TABLET;

CHILD HEALTH CARE; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURCHASING; HIV INFECTIONS; HUMAN; PEDIATRICS; SUPPLY AND DISTRIBUTION; TABLET;

ANTI-HIV AGENTS; DIDANOSINE; DRUG INDUSTRY; HIV INFECTIONS; HUMANS; PEDIATRICS; TABLETS;

EID: 77957200579     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61488-2     Document Type: Letter

References (1)

1. M Kamal-Yanni, K Nichols, E Tallah, N Otwoma Open letter to Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb Lancet 375 2010 2213